Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Already, significant harm has been done to inhibit progress combating HIV/AIDS, and the next four years could return us to ...

The goal of brushing one’s teeth is to have fresh breath and prevent cavities. But the effect of toothpaste on the complex ...

HIV/AIDS continues to disproportionately affect Black Americans, despite overall progress in reducing infection rates.

The company is planning a Phase 3 trial for the new formulation of lenacapavir, Stat reports. Other pharma and technology news is on microplastics and the spread of antibiotic-resistant superbugs; a ...